medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2006, Number 1

<< Back Next >>

Ann Hepatol 2006; 5 (1)

The use of TIPS in chronic liver disease

Wong F

Language: English
References: 98
Page: 5-15
PDF size: 132.74 Kb.


Text Extraction

The development of cirrhosis and portal hypertension in the natural history of chronic liver disease is associated with many complications. A transjugular intrahepatic portosystemic stent shunt (TIPS) is a metal prosthesis that has been shown to be very effective in lowering sinusoidal portal pressure, and therefore is effective in the management of complications of cirrhosis, especially those related to portal hypertensive bleeding and sodium and water retention. In patients with acute variceal bleeding not responding to pharmacologic and endoscopic treatments, a reduction of the hepatic venous pressure gradient to ‹ 12 mmHg or by › 20% with TIPS has been shown to be effective in controlling the acute bleed and in preventing rebleeding. For stable patients whose acute variceal bleed is controlled, TIPS is equal to combined beta-blocker and band ligation in the prevention of recurrent variceal bleed. TIPS is also more effective than large volume paracentesis in the control of refractory ascites, and may confer a survival advantage over repeated large volume paracentesis. TIPS has also been used in the management of other complications related to portal hypertension including ectopic varices, hepatic hydrothorax, and hepatorenal syndrome with some success, but experience is still rather limited. Miscellaneous uses include treatment of Budd Chiari Syndrome, portal hypertensive gastropathy and hepatopulmonary syndrome. Careful patient selection is vital to a successful outcome, as patients with severe liver dysfunction tend to die post-TIPS despite a functioning shunt. All patients who require a TIPS for treatment of complications of cirrhosis should be referred for consideration of liver transplant.


REFERENCES

  1. Collins JC, Sarfeh IJ. Surgical management of portal hypertension. West J Med 1995; 162: 527-535.

  2. Hui AJ, Sung JJ. Endoscopic treatment of upper gastrointestinal bleeding. Curr Treat Options Gastroenterol 2005; 8: 153-162.

  3. Mela M, Mancuso A, Burroughs A. Drug treatment for portal hypertension. Ann Hepatol 2002; 1: 102-120.

  4. Mihas AA, Sanyal AJ. Recurrent variceal bleeding despite endoscopic and medical therapy. Gastroenterology 2004; 127: 621-629.

  5. Gordon JD, Colapinto RF, Abecassis M, Makowka L, Langer B, Blendis LM, Taylor B, et al. A non-operative approach to life threatening variceal bleeding. Can J Surg 1987; 30: 45-49.

  6. Huonker M, Schumacher YO, Ochs A, Sorichter S, Keul J, Rossle M. Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt. Gut 1999; 44: 743-748.

  7. Tesdal IK, Filser T, Weiss C, Holm E, Dueber C, Jaschke W. Transjugular intrahepatic portosystemic shunts: adjunctive embolotherapy of gastroesophageal collateral vessels in the prevention of variceal rebleeding. Radiology 2005; 236: 360-367.

  8. Sauer P, Theilmann L, Herrmann S, Bruckner T, Roeren T, Richter G, et al. Phenprocoumon for prevention of shunt occlusion after transjugular intrahepatic portosystemic stent shunt: a randomized trial. Hepatology 1996; 24: 1433-1436.

  9. LaBerge JM, Somberg KA, Lake JR, Gordon RL, Kerlan R, Ascher N, Roberts J, et al. Two-year outcome following transjugular intrahepatic portosystemic shunt for variceal bleeding: results in 90 patients. Gastroenterology 1995; 108: 1143-1151.

  10. Riggio O, Masini A, Efrati C, Nicolao F, Angeloni S, Salvatori FM, Bezzi M, et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol 2005; 42: 674-679.

  11. Sanyal AJ, Freedman AM, Shiffman ML, Purdum PP 3rd, Luketic VA, Cheatham AK. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study. Hepatology 1994; 20: 46-55.

  12. Wong F, Blendis LM. Transjugular intrahepatic portasystemic shunt-Tipping the sodium balance. Hepatology 1995; 22: 358-364.

  13. Pattynama PM, van Hoek B, Kool LJ. Inadvertent arteriovenous stenting during transjugular intrahepatic portosystemic shunt procedure and the importance of hepatic artery perfusion. Cardiovasc Intervent Radiol 1995; 18: 192-195.

  14. Sze DY, Vestring T, Liddell RP, Kato N, Semba CP, Razavi MK, Kee ST, et al. Recurrent TIPS failure associated with biliary fistulae: treatment with PTFE-covered stents. Cardiovasc Intervent Radiol 1999; 22: 298-304.

  15. Saxon RR, Mendel-Hartvig J, Corless CL, Rabkin J, Uchida BT, Nishimine K, Keller F. Bile duct injury as a major cause of stenosis and occlusion in transjugular intrahepatic portosystemic shunts: comparative histopathologic analysis in humans and swine. J Vasc Interv Radiol 1996; 7: 487-497.

  16. Boyer TD. Transjugular intrahepatic portosystemic shunt: Current status. Gastroenterology 2003; 124: 1700-1710.

  17. Muller-Hulsbeck S, Hopfner M, Hilbert C, Kramer-Hansen H, Heller M. Mechanical thrombectomy of acute thrombosis in transjugular intrahepatic portosystemic shunts. Invest Radiol 2000; 35: 385-391.

  18. Sanyal AJ, Freedman AM, Luketic VA, Purdum PP 3rd, Shiffman ML, DeMeo J, Cole PE, et al. The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts. Gastroenterology 1997; 112: 889-898.

  19. Barrio J, Ripoll C, Banares R, Echenagusia A, Catalina M, Camunez F, Simo G, et al. Comparison of transjugular intrahepatic portosystemic shunt dysfunction in PTFE-covered stent-grafts versus bare stents. Eur J Radiol 2005; 55: 120-124.

  20. Angermayr B, Cejna M, Koenig F, Karnel F, Hackl F, Gangl A, Peck-Radosavljevic M. Vienna TIPS Study Group. Survival in patients undergoing transjugular intrahepatic portosystemic shunt: PTFE-covered stent grafts versus bare stents. Hepatology 2003; 38: 1043-1050.

  21. Rossi P, Salvatori F, Fanelli F, Bezzi M, Rossi M, Marcelli G, Pepino D, et al. Polytetrafluorethylene-covered stent-graft for transjugular intrahepatic portosystemic shunt creation: 3-year experience. Radiology 2004; 231: 820-830.

  22. Sanyal AJ, Freedman AM, Shiffman ML, Purdum PP III, Luketic VA, Cheatham AK. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study. Hepatology 1994; 20: 46-55.

  23. Jalan R, Elton RA, Redhead DN, Finlayson ND, Hayes PC. Analysis of prognostic variables in the prediction of mortality, shunt failure, variceal rebleeding and encephalopathy following the transjugular intrahepatic portosystemic stent-shunt for variceal haemorrhage. J Hepatol 1995; 23: 123-128.

  24. D’Amico G, Luca A, Morabito A, Miraglia R, D’Amico M. Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology 2005; 129: 1282-1293.

  25. Salerno F, Merli M, Riggio O, Cazzaniga M, Valeriano V, Pozzi M, Nicolini A, Salvatori F, and GIST. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 2004; 40: 629–635.

  26. Venturini I, Ferrieri A, Farina F, Cosenza F, Avallone R, Corsi L, Baraldi M, et al. Evaluation of rifaximin, placebo and lactulose in reducing the levels of benzodiazepine-like compounds in patients with liver cirrhosis: a pilot study. Drugs Exp Clin Res 2005; 31: 161-168.

  27. Sanyal AJ, Freedman AM, Purdum PP, Shiffman ML, Luketic VA. The hematologic consequences of transjugular intrahepatic portosystemic shunts. Hepatology 1996; 23: 32-39.

  28. Bouza E, Munoz P, Rodriguez C, Grill F, Rodriguez-Creixems M, Banares R, Fernandez J, et al. Endotipsitis: an emerging prostheticrelated infection in patients with portal hypertension. Diagn Microbiol Infect Dis 2004; 49: 77-82.

  29. Sanyal AJ, Reddy KR. Vegetative infection of transjugular intrahepatic portosystemic shunts. Gastroenterology 1998; 115: 110-115.

  30. Wong F, Girgrah N, Graba J, Allidina Y, Liu P, Blendis L. The effect of cirrhotic cardiomyopathy on the cardiac response to exercise in cirrhosis. Gut 2001; 49: 268-275.

  31. Wong F, Sniderman K, Liu P, Allidina Y, Sherman M, Blendis LM. The effects of transjugular intrahepatic portasystemic shunt on systemic and renal hemodynamics and sodium homeostasis in cirrhotic patients with refractory ascites. Ann Int Med 1995; 122: 816-822.

  32. Lebrec D, Giuily N, Hadengue A, Vilgrain V, Moreau R, Poynard T, Gadano A, et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. J Hepatol 1996; 25: 135-144.

  33. Thien V, Lilly L, Blendis L, Wong F. Does transjugular intrahepatic portosystemic stent shunt (TIPS) increase the risk for the development of hepatocellular carcinoma? [Abstract] Hepatology 2005; 42 (Suppl 1): 202A.

  34. Banares R, Nunez O, Escudero M, Fernandez C, Vaquero J, Beceiro I, Echenagusia A, et al. Patients with cirrhosis and bare-stent TIPS may have increased risk of hepatocellular carcinoma. Hepatology 2005; 41: 566-571.

  35. de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005; 43: 167-176.

  36. Armonis A, Patch D, Burroughs AK. Hepatic venous pressure measurement: An old test as new prognostic marker in cirrhosis? Hepatology 1997; 25: 245-248.

  37. Feu F, Garcia-Pagan JC, Bosch J, Luca A, Teres J, Escorsell A, Rodes J. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995; 346: 1056-1059.

  38. Rossle M, Siegersterrer V, Olschewski M, Ochs A, Berger E, Haag K. How much reduction in portal pressure is necessary to prevent variceal rebleeding? A longitudinal study in 225 patients with transjugular intrahepatic portosystemic shunts. Am J Gastroenterol 2001; 96: 3379-3383.

  39. Monescillo A, Martinez-Lagares F, Ruiz-del-Arbol L, Sierra A, Guevara C, Jimenez E, Marrero JM, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology 2004; 40: 793-801.

  40. Vangeli M, Patch D, Burroughs AK. Salvage tips for uncontrolled variceal bleeding. J Hepatol 2002; 37: 703-704.

  41. Rossle M. When endoscopic therapy or pharmacotherapy fails to control variceal bleeding: what should be done? Immediate control of bleeding by TIPS? Langenbecks Arch Surg 2003; 388: 155-162.

  42. Burroughs AK, Patch D. Transjugular intrahepatic portosystemic shunt. Semin Liver Dis 1999; 19: 457-473.

  43. Patch D, Nikolopoulou V, McCormick A, Dick R, Armonis A, Wannamethee G, Burroughs A. Factors related to early mortality after transjugular intrahepatic portosystemic shunt for failed endoscopic therapy in acute variceal bleeding. J Hepatol 1998; 28: 454-460.

  44. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1981; 80: 800-809.

  45. de la Pena J, Brullet E, Sanchez-Hernandez E, Rivero M, Vergara M, Martin-Lorente JL, Garcia Suarez C. Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial. Hepatology 2005; 41: 572-578.

  46. Spina GP, Henderson JM, Rikkers LF, Teres J, Burroughs AK, Conn HO, Pagliaro L, et al. Distal splenorenal shunt versus endoscopic sclerotherapy in the prevention of variceal bleeding. A meta-analysis of 4 randomized clinical trials. J Hepatol 1992; 16: 338-345.

  47. Boyer TD, Haskal ZJ. American Association for the Study of Liver Diseases. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology 2005; 41: 386-400.

  48. Papatheodoridis GV, Goulis J, Leandro G, Patch D, Burroughs AK. Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: a meta-analysis. Hepatology 1999; 30: 612-622.

  49. Norton ID, Andrews JC, Kamath PS. Management of ectopic varices. Hepatology 1998; 28: 1154-1158.

  50. Samaraweera RN, Feldman L, Widrich WC, Waltman A, Steinberg F, Greenfield A, Srinivasan M, et al. Stomal varices: percutaneous transhepatic embolization. Radiology 1989; 170: 779-782.

  51. Toumeh KK, Girardot JD, Choo IW, Andrews JC, Cho KJ. Percutaneous transhepatic embolization as treatment for bleeding ileostomy varices. Cardiovasc Intervent Radiol 1995; 18: 179-182.

  52. Sans M, Llach J, Bordas JM, Andreu V, Reverter JC, Bosch J, Mondelo F, et al. Thrombin and ethanolamine injection therapy in arresting uncontrolled bleeding from duodenal varices. Endoscopy 1996; 28: 403.

  53. Vangeli M, Patch D, Terreni N, Tibballs J, Watkinson A, Davies N, Burroughs AK. Bleeding ectopic varices-treatment with transjugular intrahepatic porto-systemic shunt (TIPS) and embolization. J Hepatol 2004; 41: 560-566.

  54. Vidal V, Joly L, Perreault P, Bouchard L, Lafortune M, Pomier-Layrargues G. Usefulness of transjugular intrahepatic portosystemic shunt in the management of bleeding ectopic varices in cirrhotic patients. Cardiovasc Intervent Radiol 2005; Nov 11 ePub.

  55. Mezawa S, Homma H, Ohta H, Masuko E, Doi T, Miyanishi K, Takada K, et al. Effect of transjugular intrahepatic portosystemic shunt formation on portal hypertensive gastropathy and gastric circulation. Am J Gastroenterol 2001; 96: 1155-1159.

  56. Kamath PS, Lacerda M, Ahlquist DA, McKusick MA, Andrews JC, Nagorney DA. Gastric mucosal responses to intrahepatic portosystemic shunting in patients with cirrhosis. Gastroenterology 2000; 118: 905-911.

  57. Urata J, Yamashita Y, Tsuchigame T, Hatanaka Y, Matsukawa T, Sumi S, Matsuno Y, et al. The effects of transjugular intrahepatic portosystemic shunt on portal hypertensive gastropathy. J Gastroenterol Hepatol 1998; 13: 977-979.

  58. Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, Angeli P, et al. The management of ascites – Report on the consensus conference of the International Ascites Club. Hepatology 2003; 38: 258-266.

  59. Gines P, Arroyo V, Quintero E, Planas R, Bory F, Cabrera J, Rimola A, et al. Comparison of paracentesis and diuretics in the treatment of cirrhosis with tense ascites. Result of a randomized study. Gastroenterology 1987; 93: 234-241.

  60. Lebrec D, Giuily N, Hadenque A, Vilgrain V, Moreau R, Poynard T, Gadano A et al. Transjugular intrahepatic portosystemic shunt: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. J Hepatology 1996; 25: 135-144.

  61. Rossle M, Ochs A, Gulberg V, Siegerstetter V, Holl J, Deibert P, Olschewski M, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000; 342: 1701-1707.

  62. Sanyal A, Gennings C, Reddy KR, Wong F, Kowdley K, Benner K, McCashland T, Morowitz C and the North American Study for Treatment of Refractory Ascites. A randomized controlled study of TIPS versus large volume paracentesis in the treatment of refractory ascites. Gastroenterology 2003; 124: 634-643.

  63. Gines P, Uriz J, Calahorra B, Garcia-Tsao, G, Kamath P, Ruiz del Arbol L, Planas R, et al. Transjugular intrahepatic portosystemic shunt versus repeated paracentesis plus intravenous albumin for refractory ascites in cirrhosis. A multicenter randomized comparative study. Gastroenterology 2002; 123: 1839-1847.

  64. Wong W, Liu P, Blendis LM, Wong F. Renal sodium handling during long-term follow-up and the effect of sodium loading in cirrhotic patients treated with TIPS for refractory ascites. Am J Med 1999; 106: 315-322.

  65. Allard JP, Chau J, Sandokji K, Blendis LM, Wong F. Effects of ascites resolution after successful TIPS on nutrition in cirrhotic patients with refractory ascites. Am J Gastroenterol 2001; 96: 2442-2447.

  66. Campbell MS, Brensinger C, Sanyal AJ, Gennings C, Wong F, Kowdley KV, Benner K, et al. Quality of life in refractory ascites: The changes and impact following transjugular intrahepatic portosystemic shunt versus medical therapy. Hepatology 2005; 42: 635-640.

  67. Borchardt J, Smirnov A, Metchnik L, Malnick S. Lesson of the week: Treating hepatic hydrothorax. BMJ 2003; 326; 751-752.

  68. Strauss RM, Martin LG, Kaufman SL, Boyer TD. Transjugular intrahepatic portal systemic shunt (TIPS) for the management of symptomatic cirrhotic hydrothorax. Am J Gastroenterol 1994; 89: 1520-1522.

  69. Gordon FD, Anastopoulos HT, Crenshaw W, Gilchrist B, McEniff N, Falchuk KR, et al. The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt. Hepatology 1997; 25: 1366-1369.

  70. Siegerstetter V, Deibert P, Ochs A, Olschewski M, Blum HE, Rossle M. Treatment of refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt: long-term results in 40 patients. Eur J Gastroenterol Hepatol 2001; 13: 529-534.

  71. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23: 164-176.

  72. Jalan R, Forrest EH, Redhead DN, Dillon JF, Hayes PC. Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man? Gut 1997; 50: 664-170.

  73. Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, Klehr HU, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000; 47: 288-295.

  74. Brensing KA, Textor J, Strunk H, Klehr HU, Schild H, Sauerbruch T. Transjugular intrahepatic portosystemic stent-shunt for hepatorenal syndrome. Lancet 1997; 349: 697-698.

  75. Testino G, Ferro C, Sumberaz A, Messa P, Morelli N, Guadagni B, Ardizzone G, et al. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation. Hepatogastroenterology 2003; 50: 1753-1755.

  76. Spahr L, Fenyves D, Nguyen VV, Roy L, Legault L, Dufresne MP, Pomier-Layrargues G. Improvement of hepatorenal syndrome by transjugular intrahepatic portosystemic shunt. Am J Gastroenterol 1995; 90: 1169-1171.

  77. Lake JR, Ring E, LaBerge J, Gordon R, Roberts J, Ascher N. Transjugular intrahepatic portacaval stent shunts in patients with renal insufficiency. Transplant Proc 1993; 25: 1766-1767.

  78. Guevara M, Gines P, Bandi JC, Gilabert R, Sort P, Jimenez W, Garcia-Pagan JC, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998; 28: 416-422.

  79. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004; 40: 55-64.

  80. Ludwig J, Hashimoto E, McGill DB, van Heerden JA. Classification of hepatic venous outflow obstruction: ambiguous terminology of the Budd-Chiari syndrome. Mayo Clin Proc 1990; 65: 51-55.

  81. Murad SD, Valla DC, de Groen PC, Zeitoun G, Hopmans J, Haagsma EB, et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology 2004; 39: 500-508.

  82. Menon KVN, Shah V, Kamath PS. The Budd–Chiari Syndrome. N Engl J Med 2004; 350: 578-585.

  83. Rossle M, Olschewski M, Siegerstetter V, Berger E, Kurz K, Grandt D. The Budd-Chiari syndrome: outcome after treatment with the transjugular intrahepatic portosystemic shunt. Surgery 2004; 135: 394-403.

  84. Attwell A, Ludkowski M, Nash R, Kugelmas M. Treatment of Budd-Chiari syndrome in a liver transplant unit, the role of transjugular intrahepatic porto-systemic shunt and liver transplantation. Aliment Pharmacol Ther 2004; 20: 867-873.

  85. Hernandez-Guerra M, Turnes J, Rubinstein P, Olliff S, Elias E, Bosch J, Garcia-Pagan JC. PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome. Hepatology 2004; 40: 1197-1202.

  86. Molmenti EP, Segev DL, Arepally A, Hong J, Thuluvath PJ, Rai R, Klein AS. The utility of TIPS in the management of Budd-Chiari syndrome. Ann Surg 2005; 241: 978-981.

  87. Khuroo MS, Al-Suhabani H, Al-Sebayel M, Al Ashgar H, Dahab S, Khan MQ, Khalaf HA. Budd-Chiari syndrome: long-term effect on outcome with transjugular intrahepatic portosystemic shunt. J Gastroenterol Hepatol 2005; 20: 1494-1502.

  88. Eapen CE, Velissaris D, Heydtmann M, Gunson B, Olliff S, Elias E. Favourable medium term outcome following hepatic vein re- canalization and/or TIPS for Budd Chiari syndrome. Gut 2005 Sep 20; ePub.

  89. Perello A, Garcia-Pagan JC, Gilabert R, Suarez Y, Moitinho E, Cervantes F, et al. TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology 2002; 35: 132-139.

  90. Fallon MB, Abrams GA. Pulmonary dysfunction in chronic liver disease. Hepatology 2000; 32: 859-865.

  91. Paramesh AS, Husain SZ, Shneider B, Guller J, Tokat I, Gondolesi GE, et al. Improvement in hepatopulmonary syndrome after transjugular intrahepatic portasystemic shunting: Case report and review of literature. Pediatr Transplantation 2003; 7: 157-162.

  92. Selim KM, Akriviadis EA, Zuckerman E, Chen D, Reynolds TB. Transjugular intrahepatic portosystemic shunt: a successful treatment for hepatopulmonary syndrome. Am J Gastroenterol 1998; 93: 455-458.

  93. Lasch HM, Fried MW, Zacks SL, Odell P, Johnson MW, Gerber DA, Sandhu FS, et al. Use of transjugular intrahepatic portosystemic shunt as a bridge to liver transplantation in a patient with severe hepatopulmonary syndrome. Liver Transpl 2001; 7: 147-149.

  94. Chevallier P, Novelli L, Motamedi JP, Hastier P, Brunner P, Bruneton JN. Hepatopulmonary syndrome successfully treated with transjugular intrahepatic portosystemic shunt: a three-year follow-up. J Vasc Interv Radiol 2004; 15: 647-648.

  95. Membreno F, Baez AL, Pandula R, Walser E, Lau DT. Differences in long-term survival after transjugular intrahepatic portosystemic shunt for refractory ascites and variceal bleed. J Gastroenterol Hepatol 2005; 20: 474-481.

  96. Ferral H, Gamboa P, Postoak DW, Albernaz VS, Young CR, Speeg KV, McMahan CA. Survival after elective transjugular intrahepatic portosystemic shunt creation: prediction with model for end-stage liver disease score. Radiology 2004; 231: 231-236.

  97. Chalasani N, Clark WS, Martin LG, Kamean J, Khan MA, Patel NH, Boyer TD. Determinants of mortality in patients with advanced cirrhosis after transjugular intrahepatic portosystemic shunting. Gastroenterology 2000; 118: 138-144.

  98. Schepke M, Roth F, Koch L, Heller J, Rabe C, Brensing KA, Schiedermaier P, et al. Prognostic impact of renal impairment and sodium imbalance in patients undergoing transjugular intrahepatic portosystemic shunting for the prevention of variceal rebleeding. Digestion 2003; 67: 146-153.




2020     |     www.medigraphic.com